Phio Stock Soars on Strong Cancer Trial Results

Key Highlights of Trial Success

Phio Pharmaceuticals (NASDAQ:PHIO) experienced a significant premarket stock surge of 57.8% following the announcement of positive efficacy results from its Phase 1b clinical trial for the cancer treatment PH-762.

Clinical Trial Performance Overview

The biopharmaceutical company reported that its INTASYL compound, PH-762, achieved an 85% pathological response rate in the final cohort, with 6 out of 7 patients responding positively. Notably, four of these responders achieved a complete response, signifying 100% tumor clearance. The study also highlighted a favorable safety profile, with no serious adverse events identified across all 22 enrolled patients.

Market and Future Impact

These positive data provide strong support for advancing PH-762 to the next stage of clinical trials. Phio Pharmaceuticals plans to seek guidance from the FDA in the second quarter of 2026 for the design of future studies. The company is also preparing for a pivotal non-human primate study, with necessary materials expected to be ready by March 2026, a critical step before commencing larger human trials.

Summary and Next Steps

In summary, the promising results from the PH-762 trial have significantly boosted investor confidence, reflected in the stock's sharp increase. The company's next steps involve regulatory engagement and further pre-clinical development, which will be crucial in advancing this potential cancer therapy towards market approval.

FAQ

Q: What caused Phio Pharmaceuticals' stock to rise?
A: The stock rose 57.8% in premarket trading after the company reported strong efficacy results from a Phase 1b clinical trial for its cancer treatment, PH-762.

Q: What were the key results of the clinical trial?
A: The trial showed an 85% pathological response rate in the final patient group, with four patients achieving 100% tumor clearance and no serious adverse events reported.

Source: Investing.com